Climb Bio Inc (NASDAQ:CLYM) shares, rose in value on Thursday, April 16, without any change to the previous day’s close as strong demand from buyers drove the stock to $1.26.
Actively observing the price movement in the last trading, the stock closed the session at $1.26, falling within a range of $1.24 and $1.34. The value of beta (5-year monthly) was -0.096. Referring to stock’s 52-week performance, its high was $11.55, and the low was $1.05. On the whole, CLYM has fluctuated by -6.67% over the past month.
With the market capitalization of Climb Bio Inc currently standing at about $85.02 million, investors are eagerly awaiting this quarter’s results, scheduled for on 2025-Mar-24.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that CLYM’s technical picture suggests that short-term indicators denote the stock is a 50% Sell on average. However, medium-term indicators have put the stock in the category of 100% Sell while long-term indicators on average have been pointing out that it is a 100% Sell.
The stock’s technical analysis shows that the price of CLYM currently trading nearly 1.02% and -7.60% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 47.45, while the 7-day volatility ratio is showing 11.32% which for the 30-day chart, stands at 9.92%. Furthermore, Climb Bio Inc (CLYM)’s beta value is -0.13, and its average true range (ATR) is 0.13.
A comparison of Climb Bio Inc (CLYM) with its peers suggests the former has fared considerably weaker in the market. CLYM showed an intraday change of 0.00% in last session, and over the past year, it shrunk by -72.37%%.
Data on historical trading for Climb Bio Inc (NASDAQ:CLYM) indicates that the trading volumes over the past 10 days have averaged 0.19 and over the past 3 months, they’ve averaged 266.86K. According to company’s latest data on outstanding shares, there are 67.26 million shares outstanding.
Nearly 18.89% of Climb Bio Inc’s shares belong to company insiders and institutional investors own 76.96% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 2.2 million shares as on 2025-03-31, resulting in a short ratio of 12.02. According to the data, the short interest in Climb Bio Inc (CLYM) stood at 449.00 of shares outstanding as of 2025-03-31; the number of short shares registered in 2025-02-28 reached 2.0 million. The stock has fallen by -30.00% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the CLYM stock heading into the next quarter.
